Damora Therapeutics (DMRA) Preferred Shares (2025 - 2026)

Damora Therapeutics' (DMRA) quarterly Preferred Shares came in at $13.5 million in Q1 2026, down 95.46% on a QoQ basis from $297.3 million in Q4 2025.

Damora Therapeutics (DMRA) Preferred Shares (2025 - 2026) Analysis & Trends

Damora Therapeutics (DMRA) has 2 years of Preferred Shares data on file, last reported at $13.5 million in Q1 2026.

  • Quarterly Preferred Shares changed N/A year-over-year to $13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.5 million (changed N/A YoY) and the FY2025 annual result came in at $297.3 million, changed N/A from the prior year.
  • Preferred Shares declined to $13.5 million in Q1 2026, from $297.3 million in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $297.3 million in Q4 2025 to a low of $13.5 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Damora Therapeutics 1.92 Bn 1.38 Bn - 117.62 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 117.62 Mn
Mar 31, 2026 13.49 Mn
Dec 31, 2025 297.29 Mn